Skip to main content
OpenTrials
Completed

NCT Number: NCT01812148

Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC)

Review of the investigators hospital experience in cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) for peritoneal mesotheliomas, using Oxaliplatin as intraperitoneal chemotherapeutic agent.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Peritoneal Mesotheliomas

Sex eligibility

All sexes

Study type

Observational

Primary location

Maisonneuve Rosemont Hospital

Montreal, Quebec, H1T 2M4, Canada

About this study

Observation of primary outcome:

  • Overall Survival
  • Disease-free survival

Influencing factors that will be observe:

  • Sex
  • Blood loss
  • Time of surgery
  • Number of resection and anastomosis
  • Peritoneal Index (PI score)
  • Cytoreductibility (CCR score)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Peritoneal mesothelioma

Exclusion criteria

  • Non resectable disease

Treatment and study plan

Cytoreductive surgery and HIPEC

Procedure

Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) with Oxaliplatin as chemotherapeutic agent

Primary outcomes

  1. Overall survival

    Time frame: 5 years

Secondary outcomes

  1. Disease-Free survival

    Time frame: 5 years

Sponsors and collaborators

Lead sponsor

Maisonneuve-Rosemont Hospital

Other

Registry information

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Mar 18, 2013
Registry last updated
Mar 18, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.